Fig. 3. Growth characteristics and drug sensitivity of L. major MRC-01 and L. major MRC-02.

a Growth curves for L. major MRC-01 and L. major MRC-02 in vitro. Representative of one experiment from two performed. b Photomicrographs of purified PNA-negative metacyclics of L. major MRC-01 (top) and L. major MRC-02 (bottom) from stationary phase cultures shown in (a). c–h In vivo lesion development in BALB/c mice following subcutaneous infection with 10⁶ metacyclics of L. major MRC-01 or L. major MRC-02 in the presence or absence of 50 mg/kg paromomycin (PM) i.p. daily for 10 days. Treatment was initiated when lesion diameter reached 3–4 mm and mice were killed if lesion size exceeded 9–10 mm in any one direction. Data are presented in aggregated form (c, f) normalised to the day of treatment initiation (shown as dotted vertical line) and as a timeline for individual mice receiving vehicle alone (d, g) or PM treatment (e, h). Data are derived from two independent experiments with 9 mice per group for L. major MRC-01 with and without treatment and L. major MRC-02 with treatment and n = 10 mice for L. major MRC-02 without treatment. Data are shown as mean ± SD. Data points within horizontal shaded area represent lesion was palpable but not measurable at <1 mm diameter. Source data are provided as a Source data file.